Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney, liver, and metabolic diseases. The company's key focus is the development of its investigational product candidate, sparsentan. This novel therapy is in late-stage development for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can lead to end-stage kidney disease.
Travere Therapeutics has made significant strides in its mission, marked by several recent achievements. The company reported positive topline data from the pivotal phase-III PROTECT study of sparsentan in IgAN, showing a substantial reduction in proteinuria and potential long-term benefits in preserving kidney function. This led to the conditional marketing authorization of sparsentan under the brand name FILSPARI® in Europe and anticipated full approval in the U.S.
Additionally, Travere Therapeutics is advancing other innovative therapies. The company is exploring the potential of pegtibatinase as the first disease-modifying treatment for classical homocystinuria (HCU), with topline data expected in 2026.
Travere's strategic partnerships, such as with CSL Vifor, amplify its reach and impact. CSL Vifor has exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand. Together, these companies are dedicated to bringing promising treatments to patients worldwide.
The company's financial condition remains robust, supported by a strong pipeline and successful trials. Travere's commitment to the rare disease community is evidenced by its relentless pursuit of better treatment options and its collaborative efforts with patients, families, and caregivers.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in four major investor conferences during March 2025. The company will present at the TD Cowen 45th Annual Health Care Conference on March 3 at 9:10 a.m. ET and the Leerink Partners Global Biopharma Conference on March 11 at 9:20 a.m. ET. Additional appearances include the Barclays 27th Annual Global Healthcare Conference and Jefferies Biotech on the Beach Summit, both scheduled for March 12.
Live webcasts will be available for the TD Cowen and Leerink Partners conference presentations through Travere's investor relations website at ir.travere.com/events-presentations. These webcasts will remain accessible for replay up to 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) reported strong financial results for Q4 and full year 2024. Net product sales reached $73.5 million in Q4 2024 (up from $39.9 million in Q4 2023) and $226.7 million for full year 2024 (up from $127.5 million in 2023). FILSPARI sales contributed $49.6 million in Q4 and $132.2 million for the full year.
The company plans to submit an sNDA around the end of Q1 2025 seeking traditional approval of FILSPARI for FSGS. The FDA granted full approval to FILSPARI in September 2024 for slowing kidney function decline in adults with primary IgAN. The company received 693 new patient start forms in Q4 2024.
As of December 31, 2024, Travere had cash, cash equivalents, and marketable securities of $370.7 million, including $134.7 million from a November 2024 common stock offering.
Travere Therapeutics (NASDAQ: TVTX) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the webcast through Travere's investor relations website, and a replay will be available for 30 days following the live presentation.
Travere Therapeutics (NASDAQ: TVTX) has announced inducement equity grants for ten new employees, approved by the Compensation Committee of its Board of Directors on February 10, 2025. The grants include 36,000 shares of stock options and 79,100 shares of restricted stock units (RSUs).
The stock options, priced at $21.10 per share, are non-qualified with a 10-year term. They vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over 36 months. The RSUs also follow a four-year vesting schedule, with 25% vesting annually. Both grants require continued employment with Travere and were issued outside the 2018 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
Travere Therapeutics (TVTX) has announced plans to submit a supplemental New Drug Application (sNDA) for FILSPARI to treat focal segmental glomerulosclerosis (FSGS), following a successful Type C meeting with the FDA. The submission, expected around the end of Q1 2025, will be based on data from Phase 3 DUPLEX and Phase 2 DUET studies.
If approved, FILSPARI could become the first approved medicine for FSGS, a rare kidney disorder affecting over 40,000 adults and children in the U.S. The submission is supported by recent findings from the PARASOL workgroup, which confirmed that reduction in proteinuria over 24 months is strongly associated with reduced risk of kidney failure in FSGS patients.
Travere Therapeutics (NASDAQ: TVTX) reported strong Q4 2024 performance with 693 new patient start forms for FILSPARI and approximately $50 million in FILSPARI net product sales. Total net product sales for Q4 2024 reached approximately $74 million, with full-year 2024 sales at $227 million. The company ended 2024 with $371 million in cash and equivalents.
The FDA accepted Travere's sNDA for FILSPARI liver monitoring modification in IgAN with a PDUFA date of August 28, 2025. FILSPARI has launched in Germany, Austria, Switzerland, and received UK approval. The company expects its European conditional marketing authorization to convert to full approval in 2025, triggering a $17.5 million milestone payment from CSL Vifor.
Partner Renalys Pharma expects topline results from its Phase 3 sparsentan trial for IgAN in Japan in H2 2025. The company plans to update on FSGS regulatory pathway by Q4 2024 earnings call, while the Phase 3 HARMONY Study enrollment for pegtibatinase in HCU will restart in 2026.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Eric Dube, Ph.D., is scheduled to deliver a presentation on Tuesday, January 14, 2025, at 8:15 a.m. PT.
The presentation will be accessible through a live webcast on the Investor page of Travere's website at ir.travere.com/events-presentations. For those unable to attend live, a replay of the presentation will remain available on the website for up to 30 days after the event.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, at 10:00 a.m. ET, and the Citi 2024 Global Healthcare Conference on Wednesday, December 4, at 2:30 p.m. ET. Live webcasts will be available on Travere's investor relations website, with replays accessible for 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) announced that its Board's Compensation Committee granted inducement equity grants to six new employees on November 10, 2024. The grants consist of restricted stock units (RSUs) covering 24,400 shares of common stock. While subject to the company's 2018 Equity Incentive Plan terms, these RSUs were granted outside the plan as employment inducements under Nasdaq Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.
Travere Therapeutics has completed its previously announced public offering of 8,984,375 shares of common stock at $16.00 per share, including 1,171,875 shares from the full exercise of underwriters' option. The offering generated gross proceeds of approximately $143.8 million before deducting underwriting discounts and expenses. Jefferies and Leerink Partners served as joint book-running managers, with Wedbush PacGrow as co-manager. The offering was made pursuant to a shelf registration statement that became effective on August 1, 2024.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
What is the primary focus of Travere Therapeutics?
What is sparsentan?
What recent achievements has Travere Therapeutics made?
What are the indications for FILSPARI®?
Who are Travere Therapeutics' strategic partners?
What is the potential significance of pegtibatinase?
What are the key safety considerations for FILSPARI® therapy?
What is the financial condition of Travere Therapeutics?
How does Travere Therapeutics develop its therapies?
Where can more information about Travere Therapeutics be found?
